Ascletis PharmaASCLF -4.00%38 EV-to-EBITDA is -24.02 as of Jul. 13, 2026. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 391 Biotechnology companies, Ascletis Pharma ranks worse than 255754.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ascletis Pharma's enterprise value is $1,219.22 Mil.
Ascletis Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-50.76 Mil. Therefore, Ascletis Pharma's EV-to-EBITDA for today is -24.02.
The historical rank and industry rank for Ascletis Pharma's EV-to-EBITDA or its related term are showing as below:
ASCLF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -353.19 Med: -1.49 Max: 111.3
Current: -24.15
During the past 10 years, the highest EV-to-EBITDA of Ascletis Pharma was 111.30. The lowest was -353.19. And the median was -1.49.
ASCLF's EV-to-EBITDA is ranked worse than 100% of 391
companies
in the Biotechnology industry
Industry Median: 13.14
vs ASCLF: -24.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ascletis Pharma's PE Ratio (TTM) for today is calculated as:
Ascletis Pharma's share price for today is $1.44.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascletis Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.053.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ascletis Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASCLF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Ascletis Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's EV-to-EBITDA falls into.
Ascletis Pharma's current Enterprise Value is $1,219.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascletis Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-50.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma (ASCLF) has a EV-to-EBITDA of -24.02 as of Jul. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ascletis Pharma. According to the industry distribution chart, Ascletis Pharma ranks #999999 out of 391 companies in the Biotechnology industry.
Is Ascletis Pharma's EV-to-EBITDA too high?
Ascletis Pharma's current EV-to-EBITDA is -24.02. Based on the distribution chart, Ascletis Pharma ranks #999999 out of 391 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #999999 out of 391 companies for EV-to-EBITDA. This places Ascletis Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 13.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.14, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ascletis Pharma. For the Biotechnology industry, the median EV-to-EBITDA is 13.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current EV-to-EBITDA is -24.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current EV-to-EBITDA is -24.02. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current EV-to-EBITDA is -24.02 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
EV-to-EBITDA: -24.02
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
